AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
70.22
+1.49 (2.17%)
At close: Apr 14, 2026, 4:00 PM EDT
69.80
-0.42 (-0.60%)
After-hours: Apr 14, 2026, 7:06 PM EDT
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or -23.53% compared to the previous year.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$2,255,798
Profits / Employee
-$127,231
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Agios Pharmaceuticals | 540 |
| Ocular Therapeutix | 325 |
| Syndax Pharmaceuticals | 298 |
| Zymeworks | 264 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
ANAB News
- 18 days ago - Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics - GlobeNewsWire
- 18 days ago - Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - GlobeNewsWire
- 18 days ago - First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement - GlobeNewsWire
- 6 weeks ago - Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 2 months ago - Anaptys Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
- 3 months ago - Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewsWire